StockData
aTYR PHARMA INC logo

aTYR PHARMA INC (ATYR) stock

ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$4.99−0.25 (-4.77%)

Close on Nov 17, 2026Market cap $489.46MP/E –Yield –

aTYR PHARMA price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

aTYR PHARMA's price to sales ratio was 10.4× on Apr 30, 2026, against 281.5× a year earlier. Over the last 3 years it ranged from 3.5× to 495.2×, with a median of 8.7×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 202610.4×+0.3
2025Dec 31, 202510.1×−392.1
2024Oct 31, 2024402.2×+394.5
2023Dec 29, 20237.7×+3.4
2021Apr 30, 20214.3×−0.3
2020Dec 31, 20204.5×–

More aTYR PHARMA figures

See a number that looks wrong?